GLP1_NEW

Ecc500 po

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ECC500_PO

Trials: 1
Participants in these arms: 39

Doses in this pooled treatment

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 0.45 (0.00 to 34.23)	0.63
Type 2 diabetes (adults)	Nausea	longest follow-up	Placebo	HR 5.12 (0.99 to 51.01)	0.22
Type 2 diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 4.57 (0.34 to 151)	0.31
Type 2 diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 0.82 (0.23 to 3.75)	0.67
Type 2 diabetes (adults)	Constipation	longest follow-up	Placebo	HR 1.37 (0.40 to 5.91)	0.47

Trials

NCT05654831
A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients With Type 2 Diabetes Mellitus
2022 · 52 randomized · 4 weeks